Lupin obtains FDA OK for generic Travatan ZTravoprost Ophthalmic Solution, 0.004%, is indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension. Amneal to pay over $270M for role in opioid crisisNew York Attorney General Letitia James has secured more than $2.7 billion in total for New York from opioid manufacturers, distributors and marketers. Lupin rolls out Rymti biosimilar Etanercept in Canada Rymti is indicated for the treatment of arthritis, severe axial spondyloarthritis and plaque psoriasis. Dr. Reddy's releases generic Oracea Generic Oracea is indicated for the treatment of inflammatory lesions of rosacea in adult patients. Alvotech to manufacture Humira biosimilar for Quallent Pharmaceuticals The high-concentration interchangeable biosimilar to AbbVie Biotechnology's Humira manufactured by Alvotech will be distributed under Quallent’s private-label. FDA approves Boehringer Ingelheim’s high-concentration formulation of interchangeable Humira biosimilar Cyltezo, the company’s interchangeable biosimilar to Humira, is used to treat multiple chronic inflammatory diseases. Sandoz reaches agreement with Amgen on denosumab biosimilars The agreement clears the path for the launch of Jubbonti and Wyost on May 31, 2025, or earlier under certain circumstances. Aurobindo receives FDA OK for generic Mitigare Colchicine Capsules are indicated prophylaxis of gout flares in adults. Avenacy debuts generic Integrilin for Injection Eptifibatide for Injection is indicated for use in acute coronary syndrome and percutaneous coronary intervention. Collegium announces authorized generic agreement with Hikma for Nucynta, Nucynta ER Hikma will have the exclusive right to sell the authorized generic versions of Nucynta and Nucynta ER in the United States. First Previous 34 35 36 37 38 Next Last
